GMI-1271: Additional Ph I/II data

Data from 33 evaluable patients with relapsed or refractory AML in an open-label, international Phase I/II trial showed that twice-daily GMI-1271 plus mitoxantrone, etoposide and cytarabine (MEC) led ...